<DOC>
	<DOCNO>NCT03059446</DOCNO>
	<brief_summary>This rollover study provide open-label treatment cenicriviroc ass long-term safety continue treatment cenicriviroc participant participate CENTAUR study 652-2-203 [ NCT02217475 ] .</brief_summary>
	<brief_title>Rollover Study Cenicriviroc Treatment Liver Fibrosis Participants With Nonalcoholic Steatohepatitis</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>TAK-652</mesh_term>
	<criteria>Successful completion Treatment Period 1 Treatment Period 2 , CENTAUR Study ( 6522203 ) , include Year 2 liver biopsy . Prior plan liver transplantation Other know cause chronic liver disease : Alcoholic liver disease , Primary biliary cirrhosis , Primary sclerosing cholangitis , Autoimmune hepatitis , Wilson 's disease , hemochromatosis , iron overload , Alpha1antitrypsis ( A1AT ) deficiency .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>